Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: A desirable candidate nanovaccine

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2085-2099

  Fairley, Stacie J ^a   Singh, Shree R ^a   Yilma, Abebayehu N ^a   Waffo, Alain B ^a   Subbarayan, Praseetha ^a   Dixit, Saurabh ^a   Taha, Murtada A ^a   Cambridge, Chino D ^a   Dennis, Vida A ^a  

^a ALABAMA STATE UNIVERSITY   (United States)

Author keywords

Antibody; Bacteria; Chlamydia trachomatis; Cytokines; PLGA nanoparticles; Vaccine

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYGLACTIN; RANTES; RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG STRUCTURE; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPOTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; SLOW DRUG RELEASE; SPLEEN CELL; TH1 CELL; TH17 CELL; TH2 CELL;

ANTIBODY; BACTERIA; CHLAMYDIA TRACHOMATIS; CYTOKINES; PLGA NANOPARTICLES; VACCINE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CELL LINE; CHEMOKINES; CHLAMYDIA TRACHOMATIS; CYTOKINES; FEMALE; FLOW CYTOMETRY; LACTIC ACID; MACROPHAGES; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYGLYCOLIC ACID; PORINS; RECOMBINANT PROTEINS; TH1 CELLS; VACCINES, SUBUNIT;

CHLAMYDIA TRACHOMATIS; MUS;

EID: 84878430358     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S44155     Document Type: Article

References (69)

1. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections: overviews and estimates. Geneva, Switzerland: World Health Organization; 2001. Available from: http://www.who.int/hiv/pub/sti/who_hiv_aids_2001.02.pdf. Accessed April 19, 2013.
2. World Health Organization. Global strategy for prevention and control of sexually transmitted infections: 2006-2015. Geneva, Switzerland: World Health Organization; 2007. Available from: http://apps.who. int/iris/bitstream/10665/43853/1/9789241563475_eng.pdf. Accessed April 19, 2013.
3. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2008. Atlanta, GA: Centers for Disease Control and Prevention; 2009. Available from: http://www.cdc.gov/std/stats08/surv2008-complete.pdf. Accessed April 19, 2013.
4. Norman J. Epidemiology of female genital Chlamydia trachomatis infections. Best Pract Res Clin Obstet Gynaecol. 2002;16:775-787.
5. Gonzales G F, Munoz G, Sanchez R, et al. Update on the impact of Chlamydia trachomatis infection on male fertility. Andrologia. 2004;36:1-23.
6. Stamm WE. Chlamydia trachomatis infections: progress and problems. J Infect Dis. 1999;179 Suppl 2:S380-S383.
7. Stamm W. Chlamydia trachomatis infections of the adult. In: Holmes KK, Sparling PF, Stamm WE, et al, editors. Sexually Transmitted Diseases. New York, NY: McGraw Hill Book Co; 2008.
8. Miyairi I, Ramsey KH, Patton DL. Duration of untreated chlamydial genital infection and factors associated with clearance: review of animal studies. J Infect Dis. 2010;201 Suppl 2:S96-S103.
9. Ibrahim AA, Refeidi A, El Mekki AA. Etiology and clinical features of acute epididymo-orchitis. Ann Saudi Med. 1996;16:171-174.
10. Taylor-Robinson D, Thomas BJ. The role of Chlamydia trachoma-this in genital-tract and associated diseases. J Clin Pathol. 1980;33: 205-233.
11. Tavakoli M, Craig AM, Malek M. An econometric analysis of screening and treatment of patients with suspected chlamydia. Health Care Manag Sci. 2002;5:33-39.
12. Walleser S, Salkeld G, Donovan B. The cost effectiveness of screening for genital Chlamydia trachomatis infection in Australia. Sex Health. 2006;3:225-234.
13. Honey E, Augood C, Templeton A, et al. Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies. Sex Transm Infect. 2002;78:406-412.
14. Stagg AJ. Vaccines against chlamydia: approaches and progress. Mol Med Today. 1998;4:166-173.
15. Shewen PE, Povey RC, Wilson MR. A comparison of the efficacy of a live and four inactivated vaccine preparations for the protection of cats against experimental challenge with Chlamydia psittaci. Can J Comp Med. 1980;44:244-251.
16. Longbottom D, Livingstone M. Vaccination against chlamydial infections of man and animals. Ve t J. 2006;171:263-275.
17. Su H, Messer R, Whitmire W, Hughes S, Caldwell HD. Subclinical chlamydial infection of the female mouse genital tract generates a potent protective immune response: implications for development of live attenuated chlamydial vaccine strains. Infect Immun. 2000;68:192-196.
18. Yu H, Karunakaran K P, Kelly I, et al. Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells. J Immunol. 2011;186: 3615-3621.
19. Schachter J, Dawson C. Human Chlamydial Infections. Littleton, MA: PSG Publishing Co; 1978.
20. Grayston JT, Wang S. New knowledge of chlamydiae and the diseases they cause. J Infect Dis. 1975;132:87-105.
21. Eko FO, He Q, Brown T, et al. A novel recombinant multisubunit vaccine against chlamydia. J Immunol. 2004;173:3375-3382.
22. Pal S, Peterson EM, de la Maza LM. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun. 2005;3:8153-8160.
23. Pal S, Theodor I, Peterson E, et al. Immunization with Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun. 2001;69:6240-6247.
24. Rockey D, Wang J, Lei L, et al. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines. 2009;8: 1365-1377.
25. de la Maza LM, Peterson EM. Vaccines for Chlamydia trachomatis infections. Curr Opin Investig Drugs. 2002;3:980-986.
26. Baehr W, Zhang YX, Joseph T, et al. Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc Nat Acad Sci U S A. 1988;85:4000-4004.
27. Ortiz L, Demick K P, Petersen J W, et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J Immunol. 1996;157: 4554-4567.
28. Cheng C, Bettahi I, Cruz-Fisher MI, et al. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine. 2009;27: 6239-6246.
29. Cunningham KA, Carey AJ, Lycke N, et al. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa. J Reprod Immunol. 2009;81:34-38.
30. Sun G, Pal S, Weiland J, et al. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine. 2009;27:5020-5025.
31. Igietseme JU, Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein lipophilic immune response-stimulating complexes. Infect Immun. 2000;68:6798-6806.
32. Pal S, Peterson EM, Rappuoli R, et al. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine. 2006;24:766-775.
33. Pal S, Luke CJ, Barbour AG, et al. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine. 2003;21:1455-1465.
34. Berry LJ, Hickey DK, Skelding KA, et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun. 2004;72: 1019-1028.
35. Singh SR, Hulett K, Pillai SR, et al. Mucosal immunization with recombinant MOMP genetically linked with modifed cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine. 2006;24:1213-1224.
36. Morlock M, Kolls H, Winter G, et al. Microencapsulation of rh-erythropoietin, using biodegradable poly(D,L-lactide-co-glycolide): protein stability and the effects of stabilizing excipients. Eur J Pharm Biopharm. 1997;43:29-36.
37. Takada S, Yamagata Y, Misaki M, et al. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J Control Release. 2003;88:229-242.
38. Lam XM, Duenas ET, Daugherty AL, et al. Sustained release of recom-binant human insulin-like growth factor-I for treatment of diabetes. J Control Release. 2000;67:281-292.
39. Rosas JE, Pedraz JL, Hernandez RM, et al. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunization of SPf66 encapsulated in PLGA microspheres. Vaccine. 2002;20:1707-1710.
40. Audran R, Men Y, Johansen P, et al. Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents. Pharm Res. 1998;15:1111-1116.
41. Igartua M, Hernandez RM, Esquisabel A, et al. Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA. J Control Release. 1998;56:63-73.
42. Carcaboso AM, Hernandez RM, Igartua M, et al. Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int J Pharm. 2003;260:273-282.
43. Lima KM, Rodrigues JM. Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system. Braz J Med Biol Res. 1999;32:171-180.
44. Taha M, Singh SR, Dennis VA. Biodegradable PLGA 85/15 nanopar-ticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide. Nanotechnology. 2012;23:325101.
45. Boyoglu S, Vig K, Pillai S, et al. Enhance delivery of nanoencapsulated DNA vaccine vector for respiratory syncytial virus. Nanomedicine. 2009;5:463-472.
46. Champion CI, Kickhoefer VA, Liu G, et al. A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One. 2009;4:e5409.
47. Singh SR, Dennis VA, Carter CL, et al. Immunogenicity and effcacy of recombinant RSV-F vaccine in mouse model. Vaccine. 2007;25: 6211-6223.
48. Singh SR, Dennis VA, Carter CL, et al. Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice. Viral Immunol. 2007;20:261-275.
49. Taha M, Singh SR, Hulett K, et al. A peptide containing T-cell epitopes of Chlamydia trachomatis recombinant MOMP induces systemic and mucosal antibody responses in mice. WJV. 2011;1(4):138-147.
50. Raghavendra C, Mundargi V, Babu R, et al. Nano/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125:193-209.
51. Jaganatha KS, Rao YU, Singh P, et al. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D, L-lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm. 2005;294:23-32.
52. Bayems V, Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv. 1997;72:191-202.
53. Kumar MNV, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2005; 25:1771-1777.
54. Alonso MJ, Gupla RK, Mim C, et al. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine. 1994;12: 299-306.
55. Rasmussen SJ, Eckman L, Quayle AJ, et al. Secretion of proinfamma-tory cytokines by epithelial cells in response to chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest. 1997;99:77-87.
56. Gupta R, Srivastava P, Vardhan H, et al. Host immune responses to chlamydial inclusion membrane proteins B and C in Chlamydia tra-chomatis infected women with and without fertility disorders. Reprod Biol Endocrinol. 2009;7:38.
57. Watford WT, Moriguchi M, Morinobu A, et al. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003;14:361-368.
58. Williams DM, Grubbs BG, Darville T, et al. Role for interleukin-6 in host defense against murine Chlamydia trachomatis infection. Infect Immun. 1998;66:4464-4467.
59. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2012;327:291-295.
60. Kaiko G, Horvat J, Beagley K, et al. Immunological decision making: how does the immune system decide to mount a helper T-cell response? Immunology. 2008;123:326-338.
61. Rottenberg ME, Rothfuchs ACG, Gigliotti D, et al. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modifed mice. J Immunol. 1999;162:2829-2836.
62. Rothfuch A, Kreuger M, Wigzell H, et al. Macrophages, CD4+ or CD8+ cells are each suffcient for protection against Chlamydia pneumoniae infection through their ability to secrete IFN-gamma. J Immunol. 2004;172:2407-2415.
63. Jupelli M, Guentzel M, Meier P, et al. Endogenous IFN-gamma production is induced and required for protective immunity against pulmonary chlamydial infection in neonatal mice. J Immunol. 2008;180: 4148-4155.
64. Lu H, Zhong G. Interleukin production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chla-mydia trachomatis infection. Infect Immun. 1999;67:1763-1769.
65. Johansson M, Schon K, Ward M, et al. Genital tract infection Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor defcient mice despite a strong local immunoglobulin A response. Infect Immun. 1997;65:1032-1044.
66. Cotter T W, Ramsey KH, Miranpuri GS, et al. Dissemination of Chla-mydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun. 1997;65:2145-2152.
67. Igietseme JU, Uriri IM, Kumar SN, et al. Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun. 1998;66:4030-4035.
68. Igietseme JU, Eko FO, He Q, et al. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines. 2004;3:23-34.
69. Pal S, Theodor I, Peterson EM, et al. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia tra-chomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine. 1997;15:575-582.